Back to top
more

Roche Holding (RHHBY)

(Delayed Data from OTC)

$39.24 USD

39.24
1,175,687

-0.71 (-1.78%)

Updated Oct 1, 2024 03:59 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 12% (30 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Roche's (RHHBY) Tecentriq Gets FDA Nod for Another Indication (Revised)

by Zacks Equity Research

Roche (RHHBY) immuno-oncology drug Tecentriq gets FDA approval for yet another indication of lung cancer.

Atea (AVIR) Plunges on Oral COVID Candidate Study Failure

by Zacks Equity Research

Atea (AVIR) is developing an oral drug candidate, AT-527, as a potential treatment for COVID-19 in outpatients as well as hospitalized settings in several studies.

    Biogen (BIIB) Q3 Earnings Top, Aduhelm Sales Negligible

    by Zacks Equity Research

    Biogen (BIIB) beats third-quarter estimates for both earnings and sales and ups its financial guidance for 2021.

      Roche (RHHBY) 9M21 Sales Grow on Strong COVID-19 Tests, View Up

      by Zacks Equity Research

      Roche (RHHBY) posts an encouraging performance in the third quarter and the first nine months of 2021 driven by demand for coronavirus tests due to the Delta variant and recovery in pharma sales.

      Biogen (BIIB) to Report Q3 Earnings: What's in the Cards?

      by Zacks Equity Research

      Investor focus is likely to be on sales of new Alzheimer's drug, Aduhelm when Biogen (BIIB) reports third-quarter earnings.

        Roche's (RHHBY) Tecentriq Gets FDA Nod for Another Indication

        by Zacks Equity Research

        Roche (RHHBY) immuno-oncology drug Tecentriq gets FDA approval for yet another indication of lung cancer.

        Prothena (PRTA) Riding High on Alzheimer's Disease Pipeline

        by Zacks Equity Research

        Prothena (PRTA) has promising candidates for Alzheimer's disease in its pipeline. The successful development of the candidates will be a big boost for the company.

        Seagen's (SGEN) Cancer Portfolio Strong, Stiff Rivalry a Worry

        by Zacks Equity Research

        Seagen (SGEN) focuses on improving sales of its marketed drugs that are approved for different types of cancer indications. Stiff competition in the target market remains a woe.

        Exelixis (EXEL) Well Poised on Label Expansions of Caboemtyx

        by Zacks Equity Research

        The going has been good for Exelixis (EXEL) on label expansions of its lead drug, Cabometyx. The pipeline progress has been encouraging as well.

        Epizyme's (EPZM) Tazverik Aids Growth, Overdependence a Woe

        by Zacks Equity Research

        While Epizyme (EPZM) gets a significant boost with the approval of Tazverik for the treatment of follicular lymphoma and epithelioid sarcoma, the sole dependence on Tazverik for growth remains a woe.

        Merck (MRK) Seeks Emergency Nod for Oral Antiviral COVID-19 Pill

        by Zacks Equity Research

        Merck's (MRK) molnupiravir to be the first oral antiviral medicine for the treatment of COVID-19, if authorized by the FDA.

        Roche's (RHHBY) AD Drug Gets Breakthrough Therapy Status

        by Zacks Equity Research

        Roche (RHHBY) gets Breakthrough Therapy Designation for gantenerumab for Alzheime's disease, which puts the spotlight on this challenging but promising space.

        4 Reasons to Add Regeneron (REGN) Stock to Your Portfolio

        by Zacks Equity Research

        Regeneron (REGN) is expected to gain from a solid and diverse portfolio despite stiff competition for its key drugs. The promising pipeline also sets the stage for growth further.

        The Zacks Analyst Blog Highlights: Roche Holding, Exxon Mobil, Honeywell, Equinix and Aon

        by Zacks Equity Research

        The Zacks Analyst Blog Highlights: Roche Holding, Exxon Mobil, Honeywell, Equinix and Aon

        Sheraz Mian headshot

        Top Research Reports for Roche, Exxon Mobil & Honeywell

        by Sheraz Mian

        Today's Research Daily features new research reports on 16 major stocks, including Roche Holding AG (RHHBY), Exxon Mobil Corporation (XOM), and Honeywell International Inc. (HON).

        Bristol Myers (BMY) UC Candidate Fails in Phase II Study

        by Zacks Equity Research

        Bristol Myers (BMY) suffers a setback as its phase II study of deucravacitinib for the treatment of moderate to severe ulcerative colitis fails to meet primary and secondary endpoints.

        Neena Mishra headshot

        Should You Invest in Travel & Tourism ETFs Now?

        by Neena Mishra

        Travel stocks could benefit from pent-up demand as we return to normal

        Sarepta (SRPT) Begins Pivotal Study on DMD Gene Therapy

        by Zacks Equity Research

        Sarepta (SRPT) is developing its lead gene therapy candidate, SRP-9001, as a potential one-time treatment for DMD.

        BioNTech (BNTX) Begins Dosing in mRNA Cancer Vaccine Study

        by Zacks Equity Research

        BioNTech (BNTX) doses the first patient in a phase II study on its mRNA cancer vaccine candidate, BNT122, in patients with colorectal cancer.

        Regeneron (REGN) Reports Positive Data on Antibody Cocktail

        by Zacks Equity Research

        Regeneron's (REGN) phase III study assessing REGEN-COV in patients hospitalized with COVID-19 meets its primary goal.

        AstraZeneca (AZN) Up on Enhertu, Imfinzi Cancer Data at ESMO (Revised)

        by Zacks Equity Research

        AstraZeneca's (AZN) Enhertu reduces the risk of disease progression by 72% in HER2-positive metastatic breast cancer. Imfinzi plus chemotherapy triples patient survival at three years in ES-SCLC.

        Seagen (SGEN) Completes Enrollment in Colorectal Cancer Study

        by Zacks Equity Research

        Seagen (SGEN) enrolls the last patient in the phase II MOUNTAINEER study evaluating Tukysa in combination with Herceptin, and as a single agent for treating HER2-positive metastatic colorectal cancer.

        Merck (MRK) Keytruda Meets Hepatocellular Carcinoma Study Goal

        by Zacks Equity Research

        Merck's (MRK) Keytruda achieves both primary and secondary endpoints in a phase III study evaluating the drug in patients with advanced hepatocellular carcinoma.

        Regeneron (REGN) Antibody Cocktail REGEN-COV Gets WHO Recommendation

        by Zacks Equity Research

        Regeneron (REGN) monoclonal antibody cocktail is being conditionally recommended by WHO for the treatment of certain patients with COVID-19. However, the high cost is a deterrent.

        Biogen's (BIIB) Lucentis BioSimilar Byooviz Gets FDA Approval

        by Zacks Equity Research

        Biogen (BIIB) announces the approval of Byooviz, its biosimilar referencing Roche's Lucentis, by the FDA.